Trial · NCT02408926
Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand
NCT02408926, Phase 4, Completed, Universiteit Antwerpen
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand. Trials, record NCT02408926. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02408926
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand
- NCT number
- NCT02408926
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 370 participants, actual
- Lead sponsor
- Universiteit Antwerpen
- Conditions
- Pertussis
- Interventions
- Boostrix, Infanrix hexa, Quinvaxem, OPV
- First posted
- 2015-04-06
- Last updated
- 2019-10-24
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | kinetics of Pertussis toxin (PT) IgG titers in infants | from birth until 19 months of age | Measurement of anti- Pertussis Toxin (PT) immunoglobulin (IgG) antibodies at several time points following maternal vaccination during pregnancy and after infant immunization (priming and boosting) with an acellular or whole cell pertussis containing vaccine |
| Primary | kinetics of Filamentous haemagglutinin (FHA) IgG titers in infants | from birth until 19 months of age | Measurement of anti- Filamentous Haemmaglutinin (FHA) immunoglobulin (IgG) antibodies at several time points following maternal vaccination during pregnancy and after infant immunization (priming and boosting) with an acellular or whole cell pertussis containing vaccine |
| Primary | kinetics of Pertactin (Prn) IgG titers in infants | from birth until 19 months of age | Measurement of anti- Pertactin (Prn) immunoglobulin (IgG) antibodies at several time points following maternal vaccination during pregnancy and after infant immunization (priming and boosting) with an acellular or whole cell pertussis containing vaccine |
| Secondary | Functionality of the maternal anti-PT IgG antibodies in the infants as assessed with a newly validated luminescence based assay | At birth | functionality of the passively acquired anti-PT antibodies in infants following maternal vaccination during pregnancy with an acellular pertussis containing vaccine (Boostrix), as assessed with a newly validated luminescence based assay |
| Secondary | Functionality of the anti-PT IgG antibodies in the infants after vaccination assessed with a newly validated luminescence based assay | At month 7 and month 19 | To measure the functionality of the anti-PT antibodies in infants vaccinated with either an acellular pertussis containing vaccine (Infanrix hexa) or a whole cell pertussis vaccine (Quinvaxem), after maternal vacicnation during pregnancy, assessed with a newly validated luminescence based assay |
| Secondary | Efficacy of the transplacental transport of IgG as assessed by the ratio of cord and maternal titers of IgG antibodies | Birth | Efficacy as assessed by the ratio of cord and maternal titers of IgG antibodies |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers8
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02408926
GET https://conductscience.org/api/trials/v1/NCT02408926/registered